FDA Approves VYVANSE TM lisdexamfetamine Dimesylate , The First And Only Once-Daily Prodrug Stimulant To Treat ADHD In Adults

Shire plc (LSE: SHP) (NASDAQ: SHPGY,), the global specialty biopharmaceutical company, announced that it has received approval from the U.S. Food and Drug Administration (FDA) for VYVANSE(TM) (lisdexamfetamine dimesylate), for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in adults.

Keywords: